The aim of this study was to evaluate the levels of anti-GM1 in demented patients, correlating them with the type and severity of dementia as well as with the eventually coexistent polyneuropathy. Anti-GM1 concentrations were measured in the sera of 33 demented patients with a male-to-female ratio of 1:2.7 (the mean age was 69.7 years for males and 70.1 years for females). Eighty-two percent of the patients revealed increased values of anti-GM1, but only 18.2% demonstrated polyneuropathies. Fifty-nine percent of the patients suffered from vascular dementia. The most severely demented patients demonstrated a Mini-Mental State Examination score of 5 to 23 out of 30 and revealed the most increased levels of anti-GM1 (>40 EU/mL). The findings of this study are indicative of a possible correlation between the levels of anti-GM1 and the severity of dementia, mainly of the vascular type.
Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y., Matsuzaki K.Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry. 2002;41: 7385-7390.
2.
Yanagisawa K. , Odaka A., Suzuki N., Ihara Y.GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat Med. 1995;1: 1062-1066.
3.
Mandal PK, Pettegrew JWAlzheimer's disease: NMR studies of asialo (GM1) and trisialo (GT1b) ganglioside interactions with Abeta (1-40) peptide in a membrane mimic environment. Neurochem Res. 2004;29:447-453.
4.
McLaurin JA, Franklin T., Fraser PE, Chakrabartty A.Structural transitions associated with the interaction of Alzheimer β-amyloid peptides with gangliosides. J Biol Chem. 1998 ;273:4506-4515.
5.
Hayashi H., Kimura N., Yamaguchi H. et al. A seed for Alzheimer amyloid in the brain. J Neurosci. 2004;24: 4894-4902.
6.
Moschetti I.Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci. 2005;62:2283-2294.
Pitto M., Raimondo F., Zoia C., Brighina L., Ferrarese C., Masserini M.Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer's patients. Neurobiol Aging. 2005;26:833-838.
9.
Corbo M., Quattrini A., Latov N., Hays APLocalization of GM1 and Gal(beta 1-3) GalNAc antigenic determinants in peripheral nerve. Neurology. 1993;43:809-814.
10.
Ogawara K., Kuwabara S., Mori M., Hattori T., Koga M., Yuki N.Axonal Gullain Barrè syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000;48:624-631.
11.
Asahina M., Kuwabara S., Suzuki A., Hattori T.Autonomic function in demyelinating and axonal subtypes of Gullain Barrè syndrome . Acta Neurol Scand. 2002;105:44-50.
12.
Wojcik M., Ulas J., Oderfeld-Nowak B.The stimulating effect of ganglioside injections on the recovery of choline acetyltransferase activities in the hippocampus of the rat after septal lesions . Neuroscience. 1982;7: 495-499.
13.
Hadjiconstantinou M., Neff HNGM1 ganglioside: in vitro and in vivo trophic actions on central neurotransmitter systems. J Neurochem. 1998;70:1335-1344.
14.
Koch HJ, Gürtler K., Szecsey A.Correlation of MMSE, SKT and clock test scores in patients with mild and moderate dementia. Nagoya J Med Sci. 2005;67:93-100.
15.
Santacruz KS , Swagerty D.Early diagnosis of dementia. Am Fam Phys. 2001;63:703-713.
16.
Gilliam FG, Kanner AM, Sheline YIDepression and Brain Dysfunction. Basingstoke, UK: Taylor & Francis; 2005.
17.
Marzanski M.On telling the truth to patients with dementia . West J Med. 2000;173:318-323.
18.
Morris JCThe Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43: 2412-2414.
19.
Schott K., Wormstall H., Dietric M., Klein R., Batra A.Autoantibodies reactivity in serum of patients with Alzheimer's disease and other age-related dementias. Psychiatry Res. 1996;59:251-254.
20.
Voumvourakis C., Rombos A., Konstantoulakis MM, Segditsa I., Papageorgiou C.Serum anti-GM1 and anti-GD1a antibodies in patients with motor neuron disease. Acta Neurol Scand. 1992;86:599-602.
21.
Zappia M., Crescibene L., Bosco D., et al. Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand. 2002;106:54-57.
22.
Dinesh K., Manvir B., Vivekanandan S., et al. IgM anti-GM1 antibody titres in patients with monomelic amyotrophy . Neurol Ind. 2006;54:399-401.
23.
Chapman J., Sela BA, Wertman E., Michaelson DMAntibodies to ganglioside GM1 in patients with Alzheimer's disease. Neurosci Lett. 2003;86:235-300.
24.
Iwamoto N., Suzuki Y., Makino Y., Haga C., Kosaka K., Iizuka R.Cell membrane changes in brains manifesting senile plaques: an immunohistochemical study of GM1 membranous ganglioside. Brain Res. 2003;522:152-156.
25.
Carpo M., Meucci N., Allaria S., et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci. 2000; 176:144-150.
26.
Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Månsson JE, Fredman P.Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem. 2005;92:171-182.
27.
Yanagisawa K.GM1 ganglioside and the seeding of amyloid in Alzheimer's disease: endogenous seed for Alzheimer amyloid. Neuroscientist. 2005;11:250-256.
28.
Yanagisawa K., Matsuzaki K.Cholesterol-dependent aggregation of amyloid β-protein . Ann N Y Acad Sci. 2002; 977:384-386.
